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Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract illness
in infants and young children. Host immune response is implicated in both protective
and immunopathological mechanisms during RSV infection. Activation of Toll-like recep-
tor (TLR)-3 in innate immune cells by RSV can induce airway inflammation, protective
immune response, and pulmonary immunopathology. A clear understanding of RSV–host
interaction is important for the development of novel and effective therapeutic strategies.
Several studies have centered on whether probiotic microorganisms with the capacity to
stimulate the immune system (immunobiotics) might sufficiently stimulate the common
mucosal immune system to improve defenses in the respiratory tract. In this regard, it was
demonstrated that some orally administered immunobiotics do have the ability to stimulate
respiratory immunity and increase resistance to viral infections. Moreover, during the last
decade scientists have significantly advanced in the knowledge of the cellular and mol-
ecular mechanisms involved in the protective effect of immunobiotics in the respiratory
tract. This review examines the most recent advances dealing with the use of immuno-
biotic bacteria to improve resistance against viral respiratory infections. More specifically,
the article discuss the mechanisms involved in the capacity of the immunobiotic strain
Lactobacillus rhamnosus CRL1505 to modulate the TLR3-mediated immune response in
the respiratory tract and to increase the resistance to RSV infection. In addition, we review
the role of interferon (IFN)-γ and interleukin (IL)-10 in the immunoregulatory effect of the
CRL1505 strain that has been successfully used for reducing incidence and morbidity of
viral airways infections in children.
Keywords: Lactobacillus rhamnosus CRL1505, TLR3, respiratory immunity, respiratory syncytial virus,
immunobiotics
INTRODUCTION
The first isolation of human respiratory syncytial virus (RSV)
was performed in 1955 from a captive chimpanzee. The virus was
quickly identified as a major respiratory pathogen in infants and
children (1). RSV is a negative-strand, non-segmented RNA pneu-
movirus of the family Paramyxoviridae, and a highly contagious
virus. Significant epidemiological studies have characterized RSV
to be a relevant human pathogen that causes a major health burden
worldwide (World Health Organization, www.who.org).
Respiratory syncytial virus causes cold-like symptoms in most
healthy adults and children. In infants and young children pre-
disposed to respiratory illness, however, RSV infection is more
likely to move into the lower respiratory tract, leading to pneu-
monia and bronchiolitis (2). RSV has been also identified as an
important cause of morbidity and mortality in the elderly, patients
with chronic obstructive pulmonary disease, and transplant
patients (3).
During the past years, a great advance in the knowledge of
the pathogenesis and the immune response against RSV has been
achieved. RSV targets both type I alveolar and non-basilar air-
way epithelial cells and possibly alveolar macrophages. These
changes in the respiratory mucosa results in the damage of respi-
ratory epithelial cells and the impairment of their ciliary actions.
Although RSV is not a highly cytopathic virus, peribroncheal
mononuclear cell infiltration, submucosal edema, mucus secre-
tion, and sometimes syncytia are observed in the lung of RSV-
infected hosts (4). In addition, several studies demonstrated that
the host immune response to RSV is implicated in both protective
and immunopathological mechanisms. Although inflammation
elicited in response to RSV is designed to destroy, dilute, and/or
sequester the virus, it can also contribute to the injury of lung tissue
as a collateral damage. Indeed, the incapacity of the host to control
inflammation in RSV infection correlates with the difficulty to
limit virus spread, reduce the extension of lung damage and pro-
ceed onward to a phase of resolution. It is likely that understanding
the pathogenesis of RSV disease, including the immune response
to infection, will help to develop novel immunoregulatory thera-
peutic strategies and design safe and effective vaccines.
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It is clear then, that the inflammatory response to RSV is
complex, and refractory to treatments with antivirals and glu-
cocorticoids, which are the standard approaches. The immumod-
ulatory impact of probiotic is of great interest considering that
these microorganisms are able to modify the responses of mucosal
tissue to subsequent pro-inflammatory challenge. Moreover, sev-
eral studies have centered on whether probiotic microorganisms
with the capacity to stimulate the immune system (immunobi-
otics) might stimulate the common mucosal immune system to
improve respiratory tract defenses. In this regard, it was demon-
strated that some orally administered immunobiotics do have the
ability to stimulate respiratory immunity and increase resistance
to viral infections. During the last decade, scientists have signif-
icantly advanced in the knowledge of the cellular and molecular
mechanisms involved in the protective effect of immunobiotics in
the respiratory tract.
This review examines the most recent work dealing with the
use of immunobiotic strains to improve resistance against viral
respiratory infections. More specifically, the article review the
mechanisms involved in the capacity of the immunobiotic strain
Lactobacillus rhamnosus CRL1505 to beneficially modulate the
immune response triggered by Toll-like receptor (TLR)-3 acti-
vation in the respiratory tract and to increase the resistance to
RSV infection. In addition, we will discuss the role of inter-
feron (IFN)-γ and interleukin (IL)-10 in the immunoregulatory
effect of the CRL1505 strain that has been successfully used for
reducing incidence and morbidity of viral airways infections in
children (5).
INNATE IMMUNE RESPONSES AGAINST RSV
It is known that the initiation of the mucosal and systemic
immune responses to respiratory virus requires the recogni-
tion by the immune system of pathogen-associated molecu-
lar patterns (PAMPs). Recognition of viral PAMPs is achieved
by cellular receptors known as pattern recognition receptors
(PRRs) that are expressed in both respiratory epithelial cells
and immune cells. PRRs sensors include the TLRs; C-type lectin
receptors and; RNA-sensing RIG-I-like receptors (RLRs) includ-
ing melanoma differentiation-associated protein 5 (MDA5) and,
retinoic acid-inducible gene I (RIG-I) (6).
Double-stranded RNA (dsRNA) is a replication intermediate of
several virus that is able to sensitize innate immune system through
TLR3. dsRNA is observed during most RNA virus replications like
RSV. The important role of TLR3 in anti-viral immunity has been
experimentally proved using TLR3 knockout mice and an artifi-
cial dsRNA, the synthetic dsRNA polyinosinic–polycytidylic acid
[poly(I:C)]. TLR3-deficient mice have been found to have their
anti-viral immune response impaired in challenge-experiments
with dsRNA or poly(I:C) (6). Then, TLR3 is considered a major
PRR against virus in animal cells. In fact, epithelial cells from the
respiratory mucosa over-express TLR3 when challenged with res-
piratory viruses and, this overexpression of TLR3 allow cells to
detect virus and acquire resistance (7, 8).
Respiratory syncytial virus predominantly infects primary air-
way epithelial cells, but can also infect other structural airway
and immune cells. Upon viral entry and activation of signaling
complexes including TLR3 (Figure 1A) (6, 9), inflammatory
cytokines and chemokines are expressed and secreted in airway
cells (10). In addition, respiratory epithelial cells and infiltrating
leukocytes produce large amounts of anti-viral molecules, such as
type I IFN. Type I IFNs signal through its receptor and induce
the transcription of many interferon responsive genes (ISGs). The
products of these genes limit virus replication and enhance the
immune response (Figure 1B) (10).
Proliferation and activation of NK cells, as well as its anti-viral
capacities are also important for the protection against RSV. An
emerging trend born from multiple clinical studies of severely
RSV-infected infants is a failure to generate a robust NK-cell
response (11–13). In addition to their anti-viral activities, NK cells
play a crucial role in the priming of adaptive immune responses
against a variety of viral infections. Indeed, the recruitment and
activation of IFN-γ-producing NK cells to the site of inflammation
plays a critical role in the subsequent development of effector CD4
Th1 and cytotoxic T lymphocytes (CTLs) responses (14). This may
occur indirectly through NK-cell licensing of DCs (Figure 2A).
During this bidirectional cross-talk, IFN-γ released by NK cells
activates DCs to produce IL-12, which in turn feeds back on the
NK cell to further amplify IFN-γ secretion (14, 15). Of note, defec-
tive NK-cell function is strongly linked with the development of
Th2-dominated immune responses in RSV infections (16).
In addition, recent studies demonstrated an important role
for macrophages in providing an immediate pro-inflammatory
response (17), and producing type I IFN (18) following RSV infec-
tion. Additionally, macrophages clear debris later in infection, and
avoid further damage and inflammation (19). There is also evi-
dence of activated granulocytes and inflammatory cytokines the
airways of children and infants with severe RSV infection, being
neutrophils the most abundant immune cells (Figure 2B). It is
known that RSV-induced damage is produced mainly by an exces-
sive infiltration of inflammatory cells into the airways and lung.
Studies investigating the infiltration of immune cells into the lung
and airways of RSV-infected children showed that neutrophils
constituted the predominant population of infiltrating cells in
nasal and bronchoalveolar (BAL) lavages. Moreover, neutrophils
were also the most common cells found in autopsy tissues from
infants infected with RSV (12, 13, 20, 21). RSV infection of the
respiratory epithelium induces the secretion of pro-inflammatory
mediators by epithelial cells and associated immune cells. The
release of pro-inflammatory chemokines and cytokines as well as
the upregulation of adhesion molecules, such as ICAM-1, induce
and mediate the recruitment of leukocytes to the respiratory tract.
Cytokines and chemokines, such as IL-1, IL-6, IL-8, IL-18, TNF,
CCL2, CCL3, CCL5, CXCL8, and CXCL10 are significantly aug-
mented in blood, BAL, and nasal aspirates from infants infected
with RSV (12, 13, 20, 21). In particular, high levels of CXCL10 and
CXCL8 that are major chemo-attractants for macrophages, neu-
trophils, and T cells, are hallmarks of RSV-infected infants (12, 20,
22). Furthermore, the levels of some of these molecules correlated
with disease severity.
ADAPTIVE IMMUNE RESPONSES AGAINST RSV
Virus elimination and the recovery from primary viral respira-
tory infection are primarily mediated by the adaptive immune
response. Both cellular and humoral immune responses act
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FIGURE 1 | Pattern recognition receptors in respiratory anti-viral
immunity. (A)Toll-like receptor 3 (TLR3) signaling pathway. TLR3 mediates
signaling via the adaptor protein TRIF (TIR-containing adaptor molecule-1).
The TIR domain of TRIF is essential for binding to the TIR domain of TLR3.
TRIF-1 is localized in the cytoplasm of resting cells, when TLR3 is activated,
TRIF co-localizes with endosomal TLR3. Then TRIF dissociates from TLR3
and co-localize with downstream-signaling molecules. The serine-threonine
kinases, TANK-binding kinase 1 (TBK1) and IkB kinase-related kinase-e
(IKK-e) are activated once TRIF interact with them. As a result of this
activation, IRF-3 is phosphorylated. TRAF3 and NF-kB-activating kinase
(NAK)-associated protein 1 (NAP1) participates in the recruitment of IRF-3
kinases and in IRF-3 activation. This pathway results in the induction of type I
interferons (IFNs). In addition, mitogen-activated protein kinases and
(MAPK) and NF-kB pathways are activated, which results in the induction of
genes involved in inflammatory responses. (B) Anti-viral immune response
in airway epithelial cells mediated by pattern recognition receptors and type
I interferons (IFNs). Type I IFNs produced are secreted by virus-infected cells
and signal in neighboring cells through the IFN-α/β receptor complex
(IFNAR). This receptor is constituted by two protein subunits called IFNAR1
and IFNAR2, which are present on the surface of cells. Interaction of type I
IFNs with IFNAR in neighboring cells enhance the production of type I IFNs
and other inflammatory cytokines. Activation of IFNAR by IFN-α or IFN-β
leads to activation of Jak1 and Tyk2 kinases, which phosphorylate the STAT
transcription factors. Then, STAT heterodimers (STAT1/STAT2) or
homodimers (STAT1) are generated. IRF-9 together with phosphorylated
STAT1 and STAT2 form a complex called interferon-stimulated gene factor 3
(ISGF3). This complex activates the transcription of ISGs inducing an
anti-viral state in the cell.
directly to eliminate viral pathogens in the respiratory tract
(Figure 3).
The interaction of RSV with respiratory DCs results in activa-
tion and maturation of those cells, being both processes important
in establishing virus-specific immunity. The quality and durabil-
ity of the host immunity as well as the susceptibility to reinfection
are significantly influenced by these early events during the initial
immune response (23). Respiratory DCs that have acquired RSV
antigens maturate and migrate to the lung-draining lymph nodes
(LN) where they present antigens and activate antigen-specific
T cells (24). In mice, lung DCs can be divided into two major
populations: conventional DCs (cDCs) that are CD11chiMHC-IIhi
and plasmacytoid DCs (pDCs) that are CD11cintB220+. In addi-
tion, cDCs can be further divided into CD11b+CD103− cDCs
(CD11b+ cDCs) and CD11b−CD103+ cDCs (CD103+ cDCs)
(24). Both populations of cDCs (CD11b+ and CD103+) have
essentially different locations within the lung tissue. CD11b+
cDCs are located in the parenchyma of the lung and they pro-
mote the recruitment of leukocytes through the production of
pro-inflammatory chemokines. In contrast, CD103+ cDCs are
located in the basal lamina and they are able to extend dendrites
into the airway lumen, allowing them to sample potential foreign
pathogens from the airway.
After RSV challenge, the total number of lung and lung-
draining LN DCs is augmented (25). However, kinetics of DCs
mobilizations following acute RSV infection is different in the
subepithelial CD11b+ cDCs when compared with parenchymal
CD103+ DCs populations. Whereas the number of CD11b+
cDCs increases, the total number of CD103+ cDC decreases and
remained low during the course of the RSV infection (26). Migrat-
ing CD11b+ and CD103+ cDCs exhibit a mature phenotype, with
high expression of CD40, CD80, and CD86 molecules. Moreover,
both populations exhibit a similar capacity to stimulate IFN-γ
production by CD4 and CD8 T cells (26).
T cells have clear direct and indirect anti-viral effects during
RSV infection. Several studies of primary and secondary RSV
infections in mice models have demonstrated the central role
of T lymphocytes in the pathology of RSV disease. In BALB/c
mice, primary infection produces lymphocyte infiltration into the
lungs and a strong production of IFN-γ by CD8 cells. Moreover,
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FIGURE 2 | Respiratory anti-viral innate immune response. (A) Activity of
natural killer cells. Natural killer (NK) cells are involved in the elimination of
virus-infected cells because of their cytotoxic capacities. NK cells are
recruited to the lungs early after respiratory virus infection. Dendritic cells
(DCs) potentiate NK-cell activation and cytotoxicity. In addition, alveolar
macrophages are also required to activate NK cells. (B) Inflammatory
response. Epithelial cells and macrophages are crucial in the innate immune
response to respiratory virus. Several chemokines and cytokines including
IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, MIP-1a/CCL3, MIP-1b/CCL4,
RANTES/CCL5, IL-6, TNF, and IL-1 are produced by epithelial cells and
macrophages in response to virus infection. Upregulation of these cytokines
and leads to recruitment of neutrophils, which constitute the majority of
infiltrating cells. While neutrophils may mediate elimination of virus-infected
cells, their high numbers, ability to secrete further cytokines and chemokines,
and degranulation products may contribute to respiratory virus-induced
immunopathogenesis.
FIGURE 3 | Respiratory anti-viral adaptive immune response. (A)Th1
cellular immunity. Upon respiratory virus infection of lungs, CD11b+ and
CD103+ dendritic cells (DCs) are matured and migrate to the draining lymph
nodes. These DCs prime Th1 cells that return to the lung and promote viral
clearance. (B)Th17 cellular immunity. Th17 cells produce IL-17 that
co-operates with IL-1β and TNF-α to induce the release of chemokines. These
changes in the respiratory tract induce neutrophils recruitment and activate
inflammatory responses in the lung. (C) Antibody-mediated immunity.
Neutralizing antibodies have a critical role in protection from respiratory virus
infection. Serum antibodies, mainly composed of IgG, gain access to the
lungs via transduction and provide partial or complete protection against virus
replication in the lungs.
although CD4 T lymphocytes are less frequent, Th1 cells pre-
dominate even in BALB/c mice that are naturally Th2-responders
(Figure 3A). CTLs appear in the lungs at day 4, peak around
days 6–14, and are critical for viral clearance but can also con-
tribute to disease (27). Other studies have strongly associated Th2
responses with increased pathology in lungs of RSV-infected mice.
Decreased mucus production and lung inflammation were found
in acute RSV infection when the Th2 cytokine IL-4 was depleted
before viral challenge (28, 29). By contrast, decreased pulmonary
pathology is associated with Th1 responses (28, 30, 31). Deple-
tion of IL-12, a Th1 polarizing cytokine, significantly increased
production of IL-13, along with increased mucus production,
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airway resistance, and pulmonary inflammation (30). Moreover,
mice deficient in the IFN-induced transcription factor STAT1
exhibit increased production of Th2 cytokines and delayed viral
clearance (31).
It has more recently been shown that Th17 cells may also play
a role in effector mechanisms triggered in response to RSV. The
production of IL-17 by CD4+ Th17 cells has both positive and neg-
ative effects in the respiratory tract. Activated Th17 cells produce
IL-17 that induce the recruitment of neutrophils. Additionally,
it was described that IL-17 facilitates the development tertiary
lymphoid structure in infected lungs, which increase protection
against RSV infection (1, 2, 32) (Figure 3B). However, IL-17 also
acts synergistically with other pro-inflammatory factors and cells
to exacerbate inflammatory damage and alter lung function in
RSV-infected hosts. Moreover, it was recently described that IL-17
inhibits the ability of CD8+ cells to clear viral particles (1, 2, 32).
Furthermore, IL-17 enhances IL-13 production, which promotes
the activation of Th2 lymphocytes and excessive mucus produc-
tion (32). As IL-17 is known to play a role in the development
of asthma, its role in RSV pathogenesis was recently examined.
Increased IL-6 and IL-17 levels were found in the tracheal aspirate
samples from severely ill RSV-infected infants. Furthermore, IL-6,
IL-17, and IL-23 were increased in RSV-infected mice, while treat-
ment with anti-IL-17 antibodies reduced inflammation, decreased
viral load, and increased antigen-specific CD8+ T cells in the lung
(32, 33) (Figure 3B).
An effective B-cell response is also essential for resistance
against viral respiratory tract infections. B cells response is
reflected in the generation of antibodies capable of neutralizing
the virus in both the respiratory tract and serum (Figure 3C). In
this regard, a wealth of evidence indicates that mainly neutralizing
antibodies confers protection against RSV infection. The F and G
glycoproteins are the only viral antigens able to induce neutraliz-
ing antibodies as well as relatively long-lived protection in animal
models (1). It was also reported that the prophylactic administra-
tion of RSV-neutralizing polyclonal or monoclonal antibodies is
able to protect adult and infants from severe RSV disease (1,34,35).
ROLE OF TLR3 IN DEFENSE AND PATHOGENESIS OF
RESPIRATORY VIRUS
It is known that TLR3 has a complex role in viral infec-
tions. Challenge-infection experiments in TLR3−/− animals have
demonstrated that the immune response to viruses can be unaf-
fected or impaired depending on the virus type. In fact, TLR3 has
been implicated in both protective immunity and inflammatory
tissue damage during viral infections. Studies of Coxsackievirus
group B infection showed that TLR3−/−mice are more vulnerable
to the pathogen than wild-type mice, when considering myocardi-
tis severity and mortality (36). In the hearts of coxsackievirus-
infected TLR3-deficient mice, there was an impaired expression
of IL-12p40, IL-1β, and IFN-γ, but not IFN-β, when compared
with wild-type mice. On the other hand, it was reported that
TLR3−/− mice are more resistant to the infection with West Nile
virus, indicating an important role of TLR3 in viral pathogenesis
(37). It was shown that inflammatory responses and neuropathol-
ogy as well as the viral load in the brain were significantly lower in
TLR3−/−mice compared with wild-type animals. The work clearly
demonstrated that TLR3-mediated enhanced cytokine production
and that this inflammatory response was critical for the alteration
of the blood-brain barrier. Moreover, the magnitude of the inflam-
matory damage in the blood–brain barrier correlated with viral
entry into the brain and the severity of lethal encephalitis.
In respiratory viral infections such as influenza virus or RSV,
inflammatory response mediated by TLR3 also appears to affect
the pathology induced by the virus as well as host survival.
Acute pneumonia is considered one of the most severe compli-
cations of influenza virus infection. Pneumonia develops rapidly
and often results in respiratory failure and death. Remarkably,
it was reported that TLR3-deficient animals are more resistant
than wild-type mice to influenza virus A challenge (8). Authors
described that lungs of wild-type animals presented a black hem-
orrhaged lung surface indicating a sever injury, whereas lungs
obtained from TLR3−/− knockdown mice showed only diffuse
hemorrhagic foci. These results suggested that lesions induced by
influenza virus A are reduced in the absence of TLR3. Lung tis-
sue injuries correlated with a strong inflammatory response in the
lungs of wild-type mice after influenza challenge, which is critically
reduced in TLR3−/− animals (8). Among leukocytes infiltrating
the lungs of infected mice, macrophages and CD8+ T cells were the
predominant immune cells in infected wild-type animals. How-
ever, in TLR3−/− mice the number of CD8+ T lymphocytes was
significantly lower than the one found in wild-type animals. Like-
wise, a significant reduction of the number of macrophages was
observed in TLR3−/− mice. On the contrary, neutrophils number
in the lungs of TLR3−/− animals was 1.5 times higher than in wild-
type mice (8). Remarkably, the study showed that TLR3 deficiency
caused a significant reduction of cytokine synthesis, including
IL-6, IL-12p40/p70, and RANTES while other cytokines such as
IFN-γ, G-CSF, IL-9, eotaxin, MCP-5, and IL-10 were increased
in TLR3−/− versus wild-type lungs (8). Overall, it emerges that
TLR3-mediated inflammatory response would be a key point in
the clinical manifestations of influenza virus-induced pneumonia.
The roles of inflammation, in general, and TLR3 in particular, in
the pathogenesis of RSV have been also investigated. BALB/c mice
have been used as a suitable animal model to explore the innate
and adaptive immune responses to human RSV (38). The first
histopathological studies of susceptible BALB/c mice challenged
with human RSV were reported by Graham et al. (39). Authors
demonstrated that lung injury was severe between days 5–8, resolv-
ing by day 10 after inoculation. Lung alterations were characterized
by perivascular and peribronchial infiltrates of inflammatory cells.
In addition, infiltration of lymphocytes and macrophages in the
alveolar spaces were described. Subsequent work identified sev-
eral pro-inflammatory cytokines and chemokines produced and
released after RSV infection, including IP-10, KC, MIP-1α, MCP-1,
RANTES, the IFN-γ regulated protein (40–42), and more recently,
IL-17 (32, 33).
TLR3 can detect the dsRNA generated during the RSV repli-
cation cycle (43). It is thought that TLR3 has no or little
effect on RSV clearance from the lungs. However, it is now
accepted that TLR3 is necessary to regulate the respiratory immune
environment. In fact, the lack of an appropriate regulation
of TLR3 activation significantly contributes to the pulmonary
immunopathology associated to RSV infection (44–46). It was
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reported that RSV-infected cells upregulate TLR3 expression and
MyD88-independent chemokines, such as IP-10/CXCL10 and
CCL5 after activation of the TLR3 signaling pathways by the virus
(44). This increased TLR3 expression in the respiratory epithelial
cells sensitizes these cells to subsequent viral dsRNA exposure and
increase the production of IL-8 via NF-kB pathway (46). Moreover,
it was demonstrated that RSV promotes a predominant Th1-type
response when TLR3 is activated during the infection (45). By
contrast, increased pathogenic Th2-biased response is generated
when TLR3 is deleted, including accumulation of eosinophils in
the lung and overproduction of Th2 cytokines and mucus (45).
These results are in line with the notion that the persistent
unregulated inflammatory responses induced by RSV in lungs,
may provide an environment that facilitates the infection with
other respiratory pathogens (47). Therefore, an appropriate mod-
ulation of respiratory TLR3 could be an interesting therapeutic
target not only for reducing RSV-induced lung inflammatory
damage, but for avoiding subsequent infections.
IMPROVEMENT OF RESPIRATORY ANTI-VIRAL IMMUNITY
WITH IMMUNOBIOTICS
Certain probiotic lactic acid bacteria (LAB) strains can exert their
beneficial effect on the host through their immunomodulatory
activity. These strains have been termed immunobiotics (48).
Although most research works concerning the immunostimula-
tory activities of probiotic LAB is focused on their effect in the
gastrointestinal tract, several recent studies have clearly demon-
strated that immunobiotics are able to improve protection against
respiratory pathogens. In fact, research from the last years indi-
cate that immunobiotic bacteria could be effectively used for the
development of new prophylactic strategies that could be effective
tools to protect against respiratory infections.
There are several lines of evidence that orally or nasally admin-
istered immunobiotics are capable of improving resistance against
viral infections in the respiratory tract. Different aspects of res-
piratory anti-viral immunity can be beneficially modulated by
immunobiotics, including the production of type I IFNs, the
activity of NK cells, the generation of Th1 responses as well
as the production of specific antibodies, and the regulation of
inflammatory-mediated lung injury (Table 1).
Maeda et al. (53) showed that orally administered heat-killed
Lactobacillus plantarum L-137 augmented the resistance against
influenza virus infection by stimulating the production of type I
IFN. The study showed that L. plantarum L-137 treatment sig-
nificantly prolonged the mean survival time in mice infected
with a mouse-adapted virulent strain of influenza virus H1N1,
and that this effect correlated the increased production of IFN-
β (53). However, detailed studies to investigate the immune
mechanisms involved in L. plantarum L-137 activity were not
performed.
Other studies emphasized the importance of IFN-γ production
and NK cells activation for the protective effect of immunobiotics
against influenza infection (55–57). Earlier studies with the known
probiotic strain Lactobacillus casei Shirota clearly demonstrated
the capacity of this bacterium to stimulate NK cells activity and
cellular immunity in the respiratory tract. Moreover, the study
showed that the Shirota strain was able to improve the resistance
of mice to influenza virus challenge (50). It was found that mice
receiving L. casei Shirota intranasally strongly induced production
of IL-12 in mediastinal lymphoid nodes (MLN) cells. In addition,
both IFN-γ and TNF-α were augmented in MLN cell cultures
from mice receiving L. casei Shirota intranasally. These changes
in MLN’s cytokine profile, induced by the immunobiotic treat-
ment, explain the improvement of NK cells stimulation and the
enhancement of the Th1 response (50). A second work of the
same group demonstrated that orally administered L. casei Shi-
rota activated the systemic and respiratory immune systems and
diminished influenza virus infection severity in both aged (51) and
infant mice (52). As observed in adult mice, the protective effect
of the Shirota strain correlated with augmented NK-cell activity
in splenocytes and lungs and enhanced IFN-γ and TNF-α produc-
tion of nasal lymphocytes. More recently, it was showed that oral
administration of heat-killed L. gasseri TMC0356 or lyophilized
L. rhamnosus GG resulted in a higher expression of pulmonary
IFN-γ and reduced pulmonary virus titers between control and
lactobacilli-treated mice (54).
In an effort to evaluate the capacity of lactobacilli to
reduce the pathogenesis of severe pneumovirus infection in vivo,
Gabryszewski et al. (61), developed a model pneumonia virus
of mice (PVM) infection. Authors showed that nasally admin-
istered L. plantarum or Lactobacillus reuteri were highly effective
for controlling inflammation induced by PVM infection and for
protecting against lethal disease. Lactobacilli treatments reduced
virus recovery and diminished granulocyte recruitment, and the
expression of pro-inflammatory cytokines including CXCL10,
CXCL1, CCL2, and TNF (Table 1). Other studies also showed the
capacity of immunobiotics to beneficially modulate the balance
between pro- and anti-inflammatory mediators during respira-
tory virus infections. Takeda et al. (58) demonstrated that L.
plantarum 06CC2, when orally administered, differentially mod-
ulated the production of cytokines during influenza infection.
The levels of IFN-γ, IL-12, and IFN-α in infected mice admin-
istered the 06CC2 strain were significantly higher than those in
the controls while the level of TNF-α was significantly lower
than that in the control mice (58). Another study investigated
whether that sublingual administration of L. rhamnosus enhanced
protection against influenza virus (63). The work reported that
immunobiotic treatment was able to augment T cell and NK-
cell activity in the respiratory mucosa, enhancing the resistance
against viral infection. Moreover, authors found that L. rham-
nosus-treated mice had improved levels of IL-12 and reduced
IL-6 and TNF-α levels in lungs when compared to controls, indi-
cating that the probiotic treatment modulated cytokine profile
in response to the infection. Taking into account that the lev-
els of the pro-inflammatory cytokines IL-6 and TNF-α have a
positive correlation with vascular dysfunction and lung inflam-
mation, these results suggest that the reduced concentrations of
some pro-inflammatory mediators would be helpful to protect
against influenza virus infection (63).
The impact of immunobiotics on anti-viral humoral response
has been also evaluated. Early studies from Yasui et al. (71)
showed that orally administered Bifidobacterium breve YIT4064
augmented the production of anti-viral antibodies including anti-
poliovirus, anti-influenza virus, and anti-rotavirus antibodies
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Table 1 | Effect of immunobiotics on viral respiratory infections.
Respiratory virus Immunobiotic treatment Protective effect Ref.
Influenza virus H1N1 Orally administered heat-killed B. breve
YIT4064
Reduction of accumulated symptom rate (49)
Improvement of survival rate
Improvement of serum IgG
Influenza virus H1N1 Nasally administered heat-killed L. casei
Shirota
Reduction of virus titer in nasal wash (50)
Improvement of survival rate
Improvement of IL-12, TNF-α, and IFN-γ in MLN
Influenza virus H1N1 Orally administered heat-killed L. casei
Shirota
Reduction of virus titer in nasal wash (51)
Improvement of NK-cell activity in spleen and lung
Improvement of TNF-α and IFN-γ in nasal lymphocytes
Influenza virus H1N1 Orally administered viable L. casei Shirota Reduction of virus titer in nasal wash (52)
Reduction of accumulated symptom rate
Improvement of NK-cell activity in lung
Improvement of IL-12 in MLN
Influenza virus H1N1 Orally administered heat-killed L. plantarum
L-137
Reduction of virus titer in lung (53)
Improvement of survival rate
Improvement of serum IFN-β
Influenza virus H1N1 Orally administered lyophilized L. gasseri
TMC0356
Reduction of virus titer in lung (54)
Reduction of clinical scores
Reduction of lung injury
Immune mechanism not studied
Influenza virus H1N1 Nasally administered heat-killed L. pentosus
S-PT84
Reduction of virus titer in BAL (55)
Improvement of NK-cell activity in lung
Improvement of IL-12 and IFN-γ in BAL
Influenza virus H1N1 Nasally administered lyophilized
L. rhamnosus GG
Improvement of survival rate (56)
Reduction of accumulated symptom rate
Reduction of lung injury
Improvement of NK-cell activity in lung
Improvement of IL-1β, TNF-α, MCP-1, and IFN-γ in lung
Influenza virus H1N1 Orally administered lyophilized B. longum
BB536
Reduction of symptom score (57)
Reduction of lung injury
Reduction body weigh loss
Improvement of IL-1β, IL-6, and IFN-γ in lung
Influenza virus H1N1 Orally administered heat-killed L. plantarum
06CC2
Reduction of virus titer in lung (58)
Reduction body weigh loss
Improvement of NK-cell activity in spleen
Improvement of INF-α, IFN-β, IFN-γ, TNF-α, IL-12, and IL-6 in BAL
Reduction of infiltrated neutrophils
Influenza virus H1N1 Orally administered heat-killed L. pentosus
b240
Improvement of survival rate (59)
Reduction of virus titer in lung
Improvement of BALF IgA and IgG
Influenza virus H1N1 Orally administered formalin treated
Lactobacilli mixture
Improvement of survival rate (60)
Reduction of lung injury
Improvement of lung IgA
Improvement of lung TNF-α and IL-12
Influenza virus H1N1 Nasally administered formalin treated
Lactobacilli mixture
Improvement of survival rate (60)
Reduction of lung injury
Improvement of lung IgA
Improvement of lung TNF-α and IL-12
(Continued)
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Table 1 | Continued
Respiratory virus Immunobiotic treatment Protective effect Ref.
Pneumonia virus of mice Nasally administered viable or heat-killed
L. plantarum ATCCBAA793
Improvement of survival rate (61)
Reduction of virus titer in lung
Suppression of virus-induced CXCL10, CCL2, CXCL1, CCL9, TNF, and
CCL24 in a MyD88-TLR signaling independent manner
Pneumonia virus of mice Nasally administered viable or heat-killed
L. plantarum ATCC23272
Improvement of survival rate (61)
Reduction of virus titer in lung
Suppression of virus-induced CXCL10, CCL2, CXCL1, CCL9, TNF, and
CCL24 in a MyD88-TLR signaling independent manner
Poly(I:C) Orally administered viable L. rhamnosus
CRL1505
Reduction of lung injury (62)
Improvement of DCs and CD4+IFN-γ+ T cells in lung and levels of
IFN-γ, IL-10, and IL-6 in BALF
Influenza virus H1N1 Sublingual administration of lyophilized
L. rhamnosus
Reduction of virus titer in lung (63)
Reduction of lung injury
Improvement of lung IgA, IL-12, and NK-cell activity and reduction of
IL-6 and TNF-α
Respiratory syncytial virus Orally administered viable L. rhamnosus
CRL1505
Reduction of virus titer in lung (64)
Reduction of lung injury
Improvement of DCs and CD4+IFN-γ+ T cells in lung and levels of
IFN-γ, IL-10, and IL-6 in BAL
Respiratory syncytial virus Nasally administered viable or heat-killed
L. rhamnosus CRL1505
Reduction of virus titer in lung (65)
Reduction of lung injury
Improvement of DCs and CD4+IFN-γ+ T cells in lung and levels of
IFN-γ, IL-10, and IL-6 in BAL
Influenza virus H1N1 Intragastric administration of L. plantarum
CNRZ1997
Reduction of virus titer in lung (66)
Reduction of weight loss and alleviation of clinical symptoms
Immune mechanism not studied
Influenza virus H1N1 Orally administered viable and non-viable
L. acidophilus L-92
Reduction of virus titer in lung (67)
Improvement of NK cells activity in lungs
Reduction of infiltrating neutrophils
Increase of IL-17 in Peyer’s patches
Influenza virus H1N1 Orally administered lyophilized L. brevis
KB290
Alleviates clinical symptoms, loss of body weight, and the
deterioration of physical conditions
(68)
Improvement of IgA and IFN-α in BAL
Influenza virus H1N1 Orally or nasally administered L. plantarum
DK119
Reduction of virus titer in lung (69)
Reduction of body weight loss
Modulation of DCs and macrophages activities in lungs
Respiratory syncytial
virus – influenza virus
H1N1
Orally administered viable L. rhamnosus
CRL1505
Reduction of virus titer in lung (70)
Reduction of lung injury
Modulation of tissue factor and thrombomodulin expression in lungs
Improvement of IFN-γ and IL-10 in lungs
after the challenges with the respective viral pathogens (71).
Moreover, a second work of the same group with the YIT4064
strain clearly demonstrated that the immunobiotic treatment
significantly improved the protection of mice against influenza
infection; and that this protective effect was related to increased
anti-influenza virus IgG titers in serum (49). More recently,
the ability of non-viable immunobiotics to improve respiratory
anti-viral immunity was evaluated. It was reported that orally
administered heat-killed lactobacilli enhanced anti-influenza anti-
bodies in the airways. Both IgA and IgG specific antibodies sig-
nificantly reduced the susceptibility of mice to influenza virus
infection (59, 60). Then, immunobiotics are capable to modu-
late the production of systemic and mucosal antibodies against
respiratory viruses (Table 1).
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We aimed to evaluate whether a probiotic yogurt contain-
ing the immunobiotic strain L. rhamnosus CRL1505 was able
to beneficially modulate both gut and non-gut related illnesses
in humans. For this purpose, we performed a randomized con-
trolled trial in children under 5 years old (62). We demonstrated
that the intervention with the immunobiotic strain CRL1505 was
able to reduce the frequency and severity of mucosal infections
(intestinal and respiratory) in young children; and that this pro-
tective effect was related to an improvement of mucosal immunity.
It was also found that in children who consumed L. rhamnosus
CRL1505, the presence of fever and the need for antibiotic treat-
ment were significantly reduced when compared to the placebo
control group, indicating less serious infections (63). We did not
study the etiology of the respiratory infections in the clinical
trial, however previous epidemiological evaluations have shown
that viral pathogens including RSV, human metapneumovirus,
influenza A virus, parainfluenza viruses, and rhinoviruses are the
major viruses responsible of respiratory tract diseases in children
in our country (72). Therefore, the findings of our study suggested
that administration of L. rhamnosus CRL1505 could be an inter-
esting tool for reducing the incidence and severity of common
childhood infectious diseases, especially those associated to viral
pathogens (62).
DISTAL MODULATION OF RESPIRATORY ANTI-VIRAL
IMMUNITY BY L. RHAMNOSUS CRL1505
Taking into consideration the results of the clinical studies, we were
interested in demonstrating the capacity of L. rhamnosus CRL1505
to improve respiratory anti-viral immunity and to gain insight
into the immunological mechanism(s) involved in the beneficial
effect. Then, we evaluated the effect of the oral administration of
L. rhamnosus CRL1505 on respiratory anti-viral immunity trig-
gered by TLR3 activation. For this purpose, we used infant and
adult BALB/c mice and the nasal administration poly(I:C) that
is and artificial dsRNA analog and TLR3 ligand, to induce lung
inflammation. This mice model allows us to imitate functional
alterations and pro-inflammatory consequences of RNA viral
infections in the lung. We showed that after nasal administration of
poly(I:C) to BALB/c mice there was an increased inflammatory cell
recruitment into the lung and production of pro-inflammatory
cytokines, that were accompanied by a marked impairment of
lung function (62) in accordance with results published by Stow-
ell et al. (73). Increased levels of albumin concentration and
lactate-dehydrogenase (LDH) activity were observed in BAL after
poly(I:C) administration indicating impaired epithelial barrier
function and respiratory epithelial cell death. Moreover, TLR3
activation by intranasal administration of poly(I:C) resulted in
neutrophils and mononuclear cells influx into the lung (43, 62, 73).
Increased levels of respiratory MCP-1, IL-6, TNF-α, and IL-
8 were observed in our in vivo experiments with BALB/c mice.
Previous in vitro studies showed that stimulation of respiratory
epithelial cells with poly(I:C) increases TLRs and transcription
factors expression and induces the secretion of multiple cytokines
and chemokines (73). Therefore, the source of pro-inflammatory
cytokines and chemokines after poly(I:C) administration may
be the airway epithelium. It was described that the profile of
pro-inflammatory mediators induced by RSV is similar to the one
triggered by poly(I:C) (43, 73), then the experimental model used
in our works resembles RSV infection. Moreover, experimental
RSV challenge in mice and RSV infection in children is character-
ized by a prominent secretion of pro-inflammatory mediators in
the respiratory tract, as mentioned before. The coordinated actions
of these pro-inflammatory mediators promote neutrophils and
monocytes/macrophages recruitment and activation in the lung
(38), also observed in our mice model (62).
Host’s inflammatory response has to be tightly regulated dur-
ing acute viral lung infection. A regulated inflammatory response
enables pathogen elimination without the detrimental effects of
inflammation on the delicate lung tissue where gas exchange
is produced. Therefore, an appropriate balance between pro-
inflammatory and anti-inflammatory factors is crucial for an
effective and safe response against RSV. In fact, it was described
that excessive IL-10 production can induce a delayed virus clear-
ance while exuberant production of TNF-α/IL-8/MCP-1 can lead
to increased immunopathology (74). During the early stages of
RSV infection, TNF-α significantly contributes to virus clear-
ance. However, overproduction of TNF-α in the late stages of
RSV infection exacerbates tissue injuries and illness (42). Inter-
estingly, it was shown that immunopathology and lethal disease
during influenza infection is prevented by IL-10 (75). IL-10 also
seems to play an important role in the control of infection sever-
ity in RSV challenged hosts (75, 76). IL-10 deficiency during RSV
infection did not affect lung viral titers. However, lack of IL-10
significantly increases the severity of RSV disease. Absence of IL-
10 allows a greater release of inflammatory cytokines, enhanced
influx of inflammatory cells, and delayed recovery (77). Then,
the reduction of MCP-1, IL-8, TNF-α, and IL-6 in the lung
after the challenge with poly(I:C) could explain, at least partially,
the capacity of L. rhamnosus CRL1505 to reduce lung injuries
(62). Moreover, IL-10 concentrations in the respiratory tract and
serum of L. rhamnosus CRL1505-treated mice were significantly
increased prior the challenge with poly(I:C). IL-10 would be
valuable for attenuating TLR3-mediated inflammatory damage in
the lungs. Consequently, L. rhamnosus CRL1505 treatment could
be used to beneficially modulate the balance between pro- and
anti-inflammatory cytokines, allowing a reduction of lung tis-
sue damage through an effective regulation of the inflammatory
response.
Oral treatment with the CRL1505 strain also increased levels
of IFN-γ in the respiratory tract after poly(I:C) challenge (62).
The higher levels of respiratory IFN-γ in L. rhamnosus CRL1505-
treated mice could be related to the increased activity lung DCs that
are able to augment CD3+CD4+IFN-γ+ T cells numbers. In addi-
tion, we found increased levels of CD11bhigh and CD103+ DCs in
lungs of L. rhamnosus CRL1505-treated mice after challenge with
poly(I:C). Moreover, an improved MHC-II expression was found
in both DCs populations when compared with controls. However,
only CD103+ DCs showed higher production of IL-12 and IFN-
γ in L. rhamnosus CRL1505-treated mice (62). In line with our
results, it was reported that priming of CD4+DO11.10CD62Lhigh
T lymphocytes with lung CD103+ DCs, induced CD4+ T cells that
produce preferably IFN-γ rather than IL-4 (78).
These results of our clinical trial and the studies in mice
clearly indicated that L. rhamnosus CRL1505 could be useful as
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a prophylactic agent to control viral respiratory virus since this
probiotic strain is a potent inducer of anti-viral cytokines. How-
ever, further research was needed to conclusively demonstrate the
protective effect of the CRL1505 strain against real viral chal-
lenges. Therefore, we next examined whether oral administration
of L. rhamnosus CRL1505 was able to reduce the susceptibility of
infant mice to RSV infection. We demonstrated that oral admin-
istration of L. rhamnosus CRL1505 contributed to a significant
decrease of RSV titers and lung tissue damage after the chal-
lenge with the respiratory pathogen (64). The protective effect
achieved by the immunobiotic strain was related to its ability
to modulate the respiratory anti-viral response. As observed in
poly(I:C) challenge-experiments, infant mice orally treated with
the CRL1505 strain showed an early increase in the levels of respi-
ratory TNF-α and IL-6 after RSV infection. The early increases of
these cytokines together with the improved levels of IFN-γ were
probably related to the higher ability of the immunobiotic bac-
terium to reduce viral loads. In addition, orally administered L.
rhamnosus CRL1505 significantly augmented IL-10, which con-
tributed to protection against inflammatory damage (64). In
fact, we demonstrated that both IFN-γ and IL-10 are neces-
sary to achieve full protection against RSV in infant mice and
that these cytokines are differently involved in the immunopro-
tective effect of L. rhamnosus CRL1505. The reduction of RSV
titers induced by the immunobiotic strain was abolished when
blocking anti-IFN-γ antibodies were used. In addition, the reduc-
tion of lung tissue injury induced by the CRL1505 strain was
partially abolished with anti-IFN-γ antibodies (64). On the con-
trary, the use of blocking anti-IL-10R antibodies did not affect
the ability of the immunobiotic strain to reduce RSV titers. How-
ever, blocking antibodies against IL-10R significantly abolished the
protective capacity of L. rhamnosus CRL1505 against lung tissue
damage (64).
L. rhamnosus CRL1505 also improved lung CD103+MHC-II+
and CD11bhighMHC-II+ DCs after RSV challenge (64). Consid-
ering that CD103+ and CD11bhigh lung DCs are able to present
RSV antigens to naïve T cells (26), and that both DCs pop-
ulations are important in the generation of CD8+ and CD4+
effectors T cells, the increase of lung DCs would have a critical
role in the immunoregulatory effect of L. rhamnosus CRL1505.
It could be speculated that the immunobiotic strain would be
able to improve protective adaptive immune response by bene-
ficially modulating DCs activity, considering that activation and
maturation of antigen presenting cells after RSV arrival to the
lung determine the quality and durability of host immunity and
influence susceptibility to reinfection (64).
Respiratory syncytial virus infection induces Th2-like inflam-
mation in the lung. Therefore, strategies that improve Th1
responses against RSV are considered beneficial to modulate the
outcome of the disease especially in young individuals. IFN-γ aug-
ments the expression of MHC-II and MCH-I in DCs and increases
the cellular Th1 anti-viral immune response. These changes sup-
press the proliferation and activation of Th2 T cells (79). Consis-
tent with this notion, L. rhamnosus CRL1505 administration to
infant mice significantly increased RSV clearance and augmented
respiratory IFN-γ levels. Then, modulation of respiratory immu-
nity induced by the immunobiotic strain might contribute to an
increase in Th1 response and thereby favor protective immunity
against respiratory viral infections such as RSV.
We were particularly interested in gaining insight into the
mechanism(s) involved in the immunoprotective capacities of
L. rhamnosus CRL1505. In vivo and in vitro experiments demon-
strated that the CRL1505 strain significantly augmented the levels
of IFN-γ, IFN-α, IFN-β, TNF-α, IL-10, and IL-6 in the intestine
and the number of CD3+CD4+IFN-γ+ T cells in Peyer’s Patches.
In addition, L. rhamnosus CRL1505 is able to improve these
cytokines in blood, particularly IFN-γ, IL-10, and IL-6. The profile
of blood cytokines was similar to the one in the intestinal fluid, sug-
gesting that levels of serum cytokines are a reflection of intestinal
changes (80). On the contrary, the analysis of respiratory cytokines
showed that only IFN-γ, IL-10,and IL-6 were increased by L. rham-
nosus CRL1505 (62). These same cytokines were augmented by
the immunobiotic strain in serum, however, it was not possible
to attribute a direct correlation between the increases in the res-
piratory tract and blood, because TNF-α, IFN-α, or IFN-β levels
were not augmented in the airways of L. rhamnosus CRL1505-
treated mice. Therefore, considering the ability of L. rhamnosus
CRL1505 to augment the number of intestinal CD3+CD4+IFN-
γ+ T cells, we hypothesized that the immunobiotic strain would
induce a mobilization of these cells into the respiratory tract.
We confirmed that this assumption was true after demonstrating
increased numbers of CD3+CD4+IFN-γ+ T in the lungs mice
orally treated with L. rhamnosus CRL1505 (62). Furthermore,
the mobilization of CD3+CD4+IFN-γ+ T cells from the intes-
tine to the airways and the higher production of IFN-γ could be
involved in the improved anti-viral state induced by L. rhamno-
sus CRL1505 that was observed in clinical studies (5). Probably,
IFN-γ secreted in response to L. rhamnosus CRL1505 stimulation
would be capable of functionally modulate the innate immune
microenvironment in the lung, inducing the activation of DCs
(64) and macrophages (81). Additionally, IFN-γ would favor the
generation of Th1 immunity with the consequent reduction of the
damaging Th2 reactions that are associated to RSV challenge (64)
(Figure 4). In addition, there is increasing information regard-
ing the involvement of Th17 cells in respiratory virus infections
such as influenza and RSV. As mentioned before, cytokines pro-
duced by Th17 cells have both positive and negative effects during
RSV infections. Considering that some works have demonstrated
the capacity of immunobiotics to beneficially modulate the Th17
response in respiratory allergy; it would be an interesting topic for
future research to evaluate the effect of L. rhamnosus CRL1505 on
Th17 response during RSV infection in infant mice.
LOCAL MODULATION OF RESPIRATORY ANTI-VIRAL
IMMUNITY BY L. RHAMNOSUS CRL1505
Considering that nasally administered antigens induce respira-
tory and systemic immune responses that are superior to those
obtained with oral immunizations, we also analyzed whether the
nasal administration of immunobiotics is capable of increasing
resistance against poly(I:C)/RSV challenges. In addition to the
CRL1505 strain, we also evaluated L. rhamnosus CRL1506, a
strain with a strong capacity to stimulate the production of type
I IFNs in intestinal epithelial cells (62, 82). Our work demon-
strated that nasally administered CRL1505 or CRL1506 strains
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FIGURE 4 | Proposed mechanism for the immunoregulatory effect of Lactobacillus rhamnosus CRL1505 on respiratory anti-viral immune responses
and resistance against respiratory syncytial virus.
were capable of modulating TLR3-triggered anti-viral respira-
tory immune response, demonstrating in addition a different
immunoregulatory effect for each immunobiotic strain. L. rham-
nosus CRL1506 significantly modulated the production of type I
IFN and IL-6 in the response to poly(I:C) or RSV challenges. On
the other hand, priming with L. rhamnosus CRL1505 effectively
improved levels of IFN-γ and IL-10 in the respiratory mucosa (83).
L. rhamnosus CRL1506 had a significant effect on epithelial cells
from the respiratory tract. It is known that type I IFNs increase the
expression of genes that are involved in innate anti-viral defenses
and the development of a strong Th1 response. Therefore, L. rham-
nosus CRL1506, through the stimulation of anti-viral defenses
in epithelial cells, could play a significant role in the improve-
ment of innate and specific immune responses against respiratory
viral infections (83). On the other hand, nasal administration
of L. rhamnosus CRL1505 augmented levels of BAL IFN-γ and
lung CD3+CD4+IFN-γ+ T indicating an improvement of the
respiratory Th1 response. Moreover, CRL1505 administration sig-
nificantly activated CD103+ DCs. Those effects were not observed
in mice orally treated with the CRL1506 strain. Then, L. rhamnosus
CRL1505 would be more efficient than L. rhamnosus CRL1506 to
stimulate CD103+ DCs and improve Th1 response in the lung
(83). In line with this notion, recent studies suggested that respi-
ratory CD103+ DCs are more potent at eliciting Th1 responses
than CD11bhigh DCs (78).
Nasal treatment with L. rhamnosus CRL1505 and CRL1506
significantly reduced lung injuries caused by poly(I:C). Both
lactobacilli augmented IL-10 production in response to TLR3
activation, however, L. rhamnosus CRL1505 was more efficient
than CRL1506 to increase the levels of this cytokine in the
lung. Additionally, the markers of lung damage were lower in
CRL1505-treated mice than in those receiving L. rhamnosus
CRL1506 (83). Therefore, there is a direct connection between
the improvement of respiratory IL-10 and the protection against
poly(I:C)-induced lung damage after immunobiotic treatment.
Moreover, our results indicate that CD3+CD4+IL-10+ T cells
would be functionally and quantitatively modulated by L. rhamno-
sus CRL1505 and that these cells would be the source of the IL-10
produced after poly(I:C) challenge (83). Recently, it was reported
that the majority of IL-10 produced during acute RSV infections
comes from CD4+ T (76). Moreover, it was suggested that this cell
population is involved in the protection against lung tissue alter-
ations. Therefore, the improved numbers of lung CD3+CD4+IL-
10+ T cells induced by nasally administered immunobiotics could
have an important role in the protection against RSV challenge.
It should be considered in addition that during respiratory infec-
tions, other cell populations are able to produce IL-10 (75, 76).
It was described that IL-10 is produced by different CD4+ T
cells during RSV infection. These cell populations include Foxp3+
regulatory T cells, IFN-γ producing Foxp3−CD4+ T cells that
coproduce IL-10, and Foxp3−CD4+ T cells that do not copro-
duce IFN-γ (76). Moreover, it was described that a small number
CD8+ T cells also produce IL-10 after RSV challenge (76). It
would be of value to investigate whether immunobiotic treatments
influence the production of IL-10 in respiratory CD4+Foxp3+,
CD4+Foxp3− IFN-γ+, CD4+Foxp3−IFN-γ−, and CD8+ T cells.
Nasal administration of L. rhamnosus CRL1505 or L. rham-
nosus CRL1506 augmented the production of pro-inflammatory
mediators and IL-10 in response to RSV infection (83). L. rham-
nosus CRL1505 was more effective than L. rhamnosus CRL1506
to improve the levels of respiratory IL-10, to protect against the
inflammatory damage, and to enhance virus clearance, similarly
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to our results using poly(I:C). This finding also supports the idea
that modulation of IL-10 is an effective way to improve the out-
come of RSV disease. In addition, our results demonstrated that
the nasal priming with immunobiotics is an interesting alternative
to achieve the immunoprotective effect in the respiratory tract;
since virus titers and lung alterations were significantly lower in
mice nasally treated with L. rhamnosus CRL1505 than in those fed
with the bacteria (62, 83) (Figure 4).
Our results also demonstrated that nasally administered
immunobiotics are more effective than orally delivered probiotics
to improve anti-viral respiratory defenses and protect against viral
infections such as RSV (62, 83).
Finally, we evaluated whether viability of the immunomodula-
tory lactobacilli was a necessary condition to achieve the protective
effect against respiratory viral infection. Some few studies reported
that nasally administered heat-killed immunobiotics are capable
of improving resistance against respiratory pathogens (50, 61, 84,
85) (Table 1). In this regard, studies by Hori et al. (50) showed
that the nasal priming with heat-killed L. casei Shirota signifi-
cantly augmented the resistance of adult BALB/c mice to influenza
virus by stimulating respiratory tract cellular immunity. L. casei
Shirota strongly induced production of IL-12 in MLN cells, which
stimulates cytotoxic T cells and NK cells, and enhances the Th1
response. Moreover, after influenza virus challenge, both TNF-α
and IFN-γ were increased in MLN cell cultures from mice nasally
treated with L. casei Shirota (50). In addition, it was reported an
improved IFN-α production and NK activity as well as a strongly
enhanced Th1 immunity in the respiratory tract of mice treated
nasally with heat-killed L. pentosus S-PT84, which were protected
against influenza virus infection (55). More recently, it was shown
that nasal priming with both live and heat-killed L. plantarum and
L. reuteri induces a full protection against the lethal pneumovirus
infection (61). That work demonstrated that nasally adminis-
tered heat-killed lactobacilli resulted in a strong regulation of
virus-induced pro-inflammatory mediators and diminished virus
recovery. The results of our recent experiments are in line with
these previous works since administration of both heat-killed L.
rhamnosus CRL1505 was effective to improve resistance of infant
mice to RSV infection and reduce lung injuries, inducing a protec-
tive effect that was similar to the observed for the viable strain (83)
(Figure 4). Interestingly, although both viable and heat-killed L.
rhamnosus CRL1506 showed a similar capacity to reduce lung RSV
titers, the viable bacteria was more effective than the heat-killed
ones to reduce lung damage after RSV challenge. These differen-
tial effects achieved by viable and heat-killed lactobacilli could be
explained by their specific capacities to modulate the production
of IL-10 and IFN-γ during RSV infection (83). The four treat-
ments evaluated were capable of increasing the levels of IFN-γ
in the respiratory tract and decreasing viral loads. On the other
hand, L. rhamnosus CRL1505 (viable and heat-killed) and viable
L. rhamnosus CRL1506 but not the heat-killed CRL1506 strain
reduced lung damage by increasing IL-10 concentrations. These
results suggest that the immunoregulatory effect of some probi-
otic bacteria can be changed after heat treatment. Therefore, not
all heat-killed bacteria derived from immunobiotic will maintain
their immunoregulatory capacities. This fact should be considered
when selecting non-viable immunobiotic strains (83).
CONCLUSION
No effective therapy strategies are available at the moment for
the prevention and treatment of RSV infections. Findings in RSV
biology and immunopathology suggest that only the inhibition
replication may not be effective for reducing lung damage during
severe infection. It should be considered that once individual expe-
riences the symptoms of RSV infection, the inflammatory response
has become uncontrolled and it is not longer linked to the repli-
cation of virus directly. Then, the use of replication inhibitors to
control lung damage is not useful. Immunoregulatory therapies
could be more effective to control the negative sequelae of severe
RSV disease.
We have demonstrated that the respiratory immune response
triggered by TLR3 activation could be beneficially modulated by
mucosal (oral and nasal) administration of immunobiotic lacto-
bacilli. Moreover, those treatments are able to increase the resis-
tance to RSV challenge in both infant and adult hosts. We also
showed that the anti-viral capacities of immunobiotic lactobacilli
are strain dependent, as it has been reported for other probiotic
effects. Comparative studies using two L. rhamnosus strains of the
same origin (32, 80) allow us to demonstrate that each lactobacilli
strain has specific immunoregulatory effects. Each strain differen-
tially modulates the immune response in the respiratory tract after
poly(I:C) stimulation. In addition, each lactobacilli confer differ-
ent degree of protection against RSV challenge and use distinct
immune mechanisms (Figure 4).
Our research also demonstrated that anti-viral respiratory
defenses are beneficially modulated by heat-killed immunobiotics.
This implies that non-viable immunobiotics could be an inter-
esting alternative as mucosal adjuvants to improve respiratory
defenses and protect against viral infections. The use of non-
viable immunobiotics or their cellular fractions could have an
important impact in the prevention of viral respiratory infec-
tions in immunocompromised hosts in which the use of live
bacteria might be dangerous. In addition, heat-killed immuno-
biotic could have several technological advantages such as eas-
ier storage, and transportation and a longer product shelf-life.
Therefore, an interesting topic for future research would be the
evaluation of non-viable L. rhamnosus CRL1505 or its cellu-
lar fractions as immunomodulators and anti-viral adjuvants in
immunocompromised hosts.
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